Prophylaxis against possible human immunodeficiency virus exposure after nonoccupational needlestick injuries or sexual assaults in children and adolescents

被引:9
作者
Babl, FE
Cooper, ER
Kastner, B
Kharasch, S
机构
[1] Boston Univ, Sch Med, Boston Med Ctr, Div Pediat Infect Dis, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Boston Med Ctr, Div Pediat Emergency Med, Boston, MA 02118 USA
来源
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE | 2001年 / 155卷 / 06期
关键词
D O I
10.1001/archpedi.155.6.680
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Nonoccupational human immunodeficiency virus (HIV) postexposure prophylaxis (PRP) for adults has been described, although the Centers for Disease Control and Prevention, Atlanta, Ga, offer no specific recommendations. There is limited information about its use in children and adolescents. Objective: To describe the current practices of physicians in pediatric infectious disease (PID) and pediatric emergency medicine (PEM) departments regarding nonoccupational HIV PEP for children and adolescents. Design: Survey. Participants: Directors of all PID and PEM departments with fellowship programs in the United States and Canada between July and November 1998. Main Outcome Measures: General questions regarding HIV PEP and questions concerning 2 scenarios (5-year-old with a needlestick injury and a 15-year-old after sexual assault). Results: The return rate was 67 (78%) of 86 for PID and 36 (75%) of 48 for PEM physicians. Fewer than 20% of physicians reported institutional policies for nonoccupational HIV PEP; 33% had ever initiated nonoccupational HIV PEP. In both scenarios, PID physicians were more likely than PEM physicians to recommend or offer HIV PEP in the first 24 hours after the incident (55 [83%] of 66 vs 20 [56%] of 36 for needlestick injuries [odds ratio, 4.0; 95% confidence interval, 1.6-10.1] and 47 [72%] of 65 vs 16 [50%] of 32 for sexual assault [odds ratio, 2.6; 95% confidence interval, 1.1-6.3]). Seven different antiretroviral agents in single, dual, or triple drug regimens administered for 2 to 12 weeks were suggested. Conclusions: Although few physicians reported institutional policies, and only one third had ever initiated HIV PEP, many would offer or recommend HIV PEP for children and adolescents within 24 hours after possible HIV exposure. A wide variation of regimens have been suggested. There is a need for a national consensus for nonoccupational HIV PEP.
引用
收藏
页码:680 / 682
页数:3
相关论文
共 17 条
[1]   Survival of HIV-1 in syringes [J].
Abdala, N ;
Stephens, PC ;
Griffith, BP ;
Heimer, R .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1999, 20 (01) :73-80
[2]   ANALYSIS OF A RAPE CASE BY DIRECT SEQUENCING OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 POL AND GAG GENES [J].
ALBERT, J ;
WAHLBERG, J ;
LEITNER, T ;
ESCANILLA, D ;
UHLEN, M .
JOURNAL OF VIROLOGY, 1994, 68 (09) :5918-5924
[3]  
*AM AC PED, 2000, 2000 RED BOOK REP CO
[4]  
[Anonymous], 1998, MMWR Recomm Rep, V47, P1
[5]   HIV postexposure prophylaxis for children and adolescents [J].
Babl, FE ;
Cooper, ER ;
Damon, B ;
Louie, T ;
Kharasch, S ;
Harris, JA .
AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2000, 18 (03) :282-287
[6]   Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005 [J].
Bottiger, D ;
Johansson, NG ;
Samuelsson, B ;
Zhang, H ;
Putkonen, P ;
Vrang, L ;
Oberg, B .
AIDS, 1997, 11 (02) :157-162
[7]  
*CDCP, 1996, MMWR-MORBID MORTAL W, V45, P468
[8]  
*CDCP, 1995, MMWR-MORBID MORTAL W, V44, P929
[9]   REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT [J].
CONNOR, EM ;
SPERLING, RS ;
GELBER, R ;
KISELEV, P ;
SCOTT, G ;
OSULLIVAN, MJ ;
VANDYKE, R ;
BEY, M ;
SHEARER, W ;
JACOBSON, RL ;
JIMENEZ, E ;
ONEILL, E ;
BAZIN, B ;
DELFRAISSY, JF ;
CULNANE, M ;
COOMBS, R ;
ELKINS, M ;
MOYE, J ;
STRATTON, P ;
BALSLEY, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) :1173-1180
[10]   Probability of heterosexual transmission of HIV: Relationship to the number of unprotected sexual contacts [J].
Downs, AM ;
DeVincenzi, I ;
Costigliola, P ;
Ricchi, E ;
Chiodo, F ;
Roumeliotou, A ;
Papaevangelou, G ;
Coutinho, RA ;
vanHaastrecht, HJA ;
Brettle, R ;
Robertson, R ;
Kraus, M ;
Heckmann, W ;
Saracco, A ;
Sacco, OL ;
Johnson, AM ;
Vandenbruaene, M ;
Goeman, J ;
Cardoso, J ;
Sobel, A ;
GonzalezLahoz, J ;
AndresMedina, R ;
Casabona, J ;
Tor, J ;
AncellePark, RA ;
Brunet, JB .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1996, 11 (04) :388-395